Because 5AR is an important trigger creating prostatic hyperplasia and AR is the main receptor related to 5AR and DHT, these results suggest a potential pharmaceutical therapy of CC on BPH treatment. The gene discussed is AR; the disease is benign prostatic hyperplasia.